![ASCO 2022: Progression-Free Survival After Second Line of Therapy (PFS-2) for Metastatic Clear Cell RCC in Patients Treated With First-Line Immunotherapy Combinations ASCO 2022: Progression-Free Survival After Second Line of Therapy (PFS-2) for Metastatic Clear Cell RCC in Patients Treated With First-Line Immunotherapy Combinations](https://www.urotoday.com/images/com-doc-importer/70-asco-2022/asco-2022-progression-free-survival-after-second-line-of-therapy-pfs-2-for-metastatic-clear-cell-rcc-in-patients-treated-with-first-line-immunotherapy-combinations/image-2.jpg)
ASCO 2022: Progression-Free Survival After Second Line of Therapy (PFS-2) for Metastatic Clear Cell RCC in Patients Treated With First-Line Immunotherapy Combinations
![Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099) - ScienceDirect Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0090825822013257-fx1.jpg)
Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099) - ScienceDirect
![Diagnostic and prognostic value of CEP55 in clear cell renal cell carcinoma as determined by bioinformatics analysis Diagnostic and prognostic value of CEP55 in clear cell renal cell carcinoma as determined by bioinformatics analysis](https://www.spandidos-publications.com/article_images/mmr/19/5/MMR-19-05-3485-g03.jpg)
Diagnostic and prognostic value of CEP55 in clear cell renal cell carcinoma as determined by bioinformatics analysis
![CLEAR Study: First-Line Lenvatinib Plus Pembrolizumab Maintains Advantage Over Sunitinib in Advanced RCC at Long-Term Follow-up CLEAR Study: First-Line Lenvatinib Plus Pembrolizumab Maintains Advantage Over Sunitinib in Advanced RCC at Long-Term Follow-up](https://dailynews.ascopubs.org/do/10.1200/ADN.23.201424/full/dn23_am23_4502_fig-1685172074857.png)
CLEAR Study: First-Line Lenvatinib Plus Pembrolizumab Maintains Advantage Over Sunitinib in Advanced RCC at Long-Term Follow-up
![Stream Final Overall Survival Results of the CLEAR Study in Renal Cell Carcinoma With Thomas Hutson, MD by Oncology Data Advisor® | Listen online for free on SoundCloud Stream Final Overall Survival Results of the CLEAR Study in Renal Cell Carcinoma With Thomas Hutson, MD by Oncology Data Advisor® | Listen online for free on SoundCloud](https://i1.sndcdn.com/artworks-tR5yPysquDEpMb2V-E5ulsg-t500x500.jpg)
Stream Final Overall Survival Results of the CLEAR Study in Renal Cell Carcinoma With Thomas Hutson, MD by Oncology Data Advisor® | Listen online for free on SoundCloud
![IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing | World Journal of Surgical Oncology | Full Text IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing | World Journal of Surgical Oncology | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12957-017-1144-1/MediaObjects/12957_2017_1144_Fig4_HTML.gif)
IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing | World Journal of Surgical Oncology | Full Text
![Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma | Anticancer Research Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/39/8/4371/F1.large.jpg)
Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma | Anticancer Research
![Six RNA binding proteins (RBPs) related prognostic model predicts overall survival for clear cell renal cell carcinoma and is associated with immune infiltration | Biomolecules and Biomedicine Six RNA binding proteins (RBPs) related prognostic model predicts overall survival for clear cell renal cell carcinoma and is associated with immune infiltration | Biomolecules and Biomedicine](https://www.bjbms.org/ojs/public/journals/1/article_6097_cover_en_US.jpg)
Six RNA binding proteins (RBPs) related prognostic model predicts overall survival for clear cell renal cell carcinoma and is associated with immune infiltration | Biomolecules and Biomedicine
Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma - Figure f3 | Aging
![Figure 1 | Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression Figure 1 | Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression](https://static.hindawi.com/articles/jo/volume-2011/628084/figures/628084.fig.001b.jpg)
Figure 1 | Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression
![Cancers | Free Full-Text | COL7A1 Expression Improves Prognosis Prediction for Patients with Clear Cell Renal Cell Carcinoma Atop of Stage Cancers | Free Full-Text | COL7A1 Expression Improves Prognosis Prediction for Patients with Clear Cell Renal Cell Carcinoma Atop of Stage](https://www.mdpi.com/cancers/cancers-15-02701/article_deploy/html/images/cancers-15-02701-g001-550.jpg)
Cancers | Free Full-Text | COL7A1 Expression Improves Prognosis Prediction for Patients with Clear Cell Renal Cell Carcinoma Atop of Stage
Artificial intelligence prediction model for overall survival of clear cell renal cell carcinoma based on a 21-gene molecular prognostic score system - Figure f1 | Aging
![MP47-11 DIFFERENTIAL ASSOCIATION OF BODY MASS INDEX ON SURVIVAL OUTCOMES IN RENAL CELL CARCINOMA: IMPACT OF TUMOR HISTOLOGY | Journal of Urology MP47-11 DIFFERENTIAL ASSOCIATION OF BODY MASS INDEX ON SURVIVAL OUTCOMES IN RENAL CELL CARCINOMA: IMPACT OF TUMOR HISTOLOGY | Journal of Urology](https://www.auajournals.org/cms/asset/bf712121-cb77-4252-977c-4cf5504d1f13/ju.0000000000002618.11f1.gif)
MP47-11 DIFFERENTIAL ASSOCIATION OF BODY MASS INDEX ON SURVIVAL OUTCOMES IN RENAL CELL CARCINOMA: IMPACT OF TUMOR HISTOLOGY | Journal of Urology
![Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging | British Journal of Cancer Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bjc.6603116/MediaObjects/41416_2006_Article_BF6603116_Fig1_HTML.gif)
Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging | British Journal of Cancer
Kaplan–Meier estimates the (A) cancer-specific and (B) overall survival... | Download Scientific Diagram
![Current Oncology | Free Full-Text | Population-Based Survival Analysis of Stage IVB Small-Cell Neuroendocrine Carcinoma in Comparison to Major Histological Subtypes of Cervical Cancer Current Oncology | Free Full-Text | Population-Based Survival Analysis of Stage IVB Small-Cell Neuroendocrine Carcinoma in Comparison to Major Histological Subtypes of Cervical Cancer](https://www.mdpi.com/curroncol/curroncol-30-00682/article_deploy/html/images/curroncol-30-00682-g001.png)
Current Oncology | Free Full-Text | Population-Based Survival Analysis of Stage IVB Small-Cell Neuroendocrine Carcinoma in Comparison to Major Histological Subtypes of Cervical Cancer
![Prognosis of ovarian clear cell cancer compared with other epithelial cancer types: A population‑based analysis Prognosis of ovarian clear cell cancer compared with other epithelial cancer types: A population‑based analysis](https://www.spandidos-publications.com/article_images/ol/19/3/ol-19-03-1947-g02.jpg)